Xenpozyme supply update for the ASMD community
November 11, 2026
The International Niemann-Pick Disease Alliance (INPDA) has shared a supply update from Sanofi about Xenpozyme® (olipudase alfa), a treatment for Acid Sphingomyelinase Deficiency (ASMD).
Sanofi anticipates supply interruptions in some countries. Based on current forecasts and expected use, global supply may be insufficient to meet global demand from mid-2027.
What does this mean for people in Australia?
The global update does not, by itself, confirm the current supply situation in Australia. The Therapeutic Goods Administration (TGA) publishes Australian medicine shortage information, which may change as new information becomes available. Please check the TGA’s Xenpozyme shortage information for the latest listing.
What should people receiving Xenpozyme do?
If you or a family member is receiving Xenpozyme and have concerns about supply or an upcoming treatment, please contact your treating clinician or specialist centre for individual advice. Do not stop or change treatment without speaking with your clinical team.
We recognise that news about medicine supply can cause concern. ANPDF will share further confirmed information relevant to the Australian ASMD community as it becomes available.
This update is for general information only and is not medical advice. Families with questions about treatment should speak with their treating clinician.
For the international update, visit INPDA’s Xenpozyme supply update. Sanofi’s information is available through its rare disease supply update page.
To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."
Ways to support NP-C in Australia:
Shop at our online NPC store
Fundraise your way! Check our free resources and inspo online.
References:
International Niemann-Pick Disease Alliance. (2026, November 10). Xenpozyme Supply Update. https://www.inpda.org/xenpozyme-supply-update/ inpda.org inpda.org
Sanofi. (2026, November 10). Supply Update. https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases/supply-update sanofi.com sanofi.com
Therapeutic Goods Administration. (n.d.). XENPOZYME olipudase alfa 20mg powder for injection vial – medicine shortage information. https://apps.tga.gov.au/Prod/msi/Search/Tradename//394103 tga.gov.au
Comments